secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001847903-23-000099
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa receives FDA Fast Track for SerpinPC in hemophilia B
-------------------------------------------------------------

- FDA granted Fast Track designation to SerpinPC, an investigational inhibitor of activated protein C.
- SerpinPC is being developed for hemophilia B, with or without inhibitors.
- Fast Track may enable expedited development and rolling review; CEO cites potential first-in-class subcutaneous therapy.
- Centessa continues to advance PRESent registrational studies for SerpinPC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000099/0001847903-23-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000099/cnta-20230522.htm
  HTML page:      https://secwatch.observer/filing/0001847903-23-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer